Clinical Trials Logo

Epilepsy clinical trials

View clinical trials related to Epilepsy.

Filter by:

NCT ID: NCT02516228 Terminated - Epilepsy Clinical Trials

Transcranial Electrical Neuromodulation for Suppressing Epileptiform Discharges

GTEN
Start date: August 2016
Phase: N/A
Study type: Interventional

This study examines the safety and feasibility of suppressing epileptic discharges through inducing long term depression of the epileptic focus with transcranial electrical neuromodulation.

NCT ID: NCT02474407 Terminated - Refractory Epilepsy Clinical Trials

Bioavailability, Safety and Tolerability of Diazepam Nasal Spray Versus Diazepam Rectal Gel (Diastat®)

Start date: June 2015
Phase: Phase 2
Study type: Interventional

This is a multi-center, open-label, crossover, pharmacokinetic, bio-availability study involving adolescents and adults with refractory (drug-resistant) epilepsy. Cohort 1 comprises the subjects used to determine the relative bioavailability of DZNS versus DRG (Diastat)

NCT ID: NCT02428348 Terminated - Epilepsy Clinical Trials

EEG@HOME (Phase 3b of the Project, Interviews)

Start date: January 2015
Phase: N/A
Study type: Interventional

The goal of this project is the development of an EEG-cap (min. 21 electrodes) with user-friendly active dry electrodes that meets the expectations of the users regarding comfort and esthetics, without losing sight of the functional and technical demands for recording high quality EEG signals. The purpose is to use the EEG-cap to investigate clinical neurological disorders (e.g. epilepsy). The EEG-cap could also be used at home so that hospital admission in the EMU can be avoided for some patients and an increasing number of patients can be examined. Phase 3 of this Project will be divided into Phase 3a and Phase 3b. In Phase 3b of the project epilepsy patients and their family will be interviewed about different EEG-cap models in development. This interview is anticipated to take approximately 1 hour. Minimum 4 - maximum 20 epilepsy patients and their family will be interviewed. The results of the interviews will be analysed by the design company pilipili nv.

NCT ID: NCT02316847 Terminated - Epilepsy Clinical Trials

An Open-Label, Safety and Tolerability Study of Chronic Intermittent Use of Diazepam Nasal Spray.

Start date: December 2014
Phase: Phase 2
Study type: Interventional

This study will assess long-term safety and tolerability of repeat dose diazepam nasal spray in adolescents and adults with cluster seizures, with a focus on potential local effects (changes in nasal mucosa, olfaction, and taste).

NCT ID: NCT02311023 Terminated - Epilepsy Clinical Trials

Intermittent Fasting in Refractory Epilepsy

Start date: March 2014
Phase: Phase 2
Study type: Interventional

This is an open trial of intermittent fasting in a group of patients with refractory seizures. Patients will continue on the diet for 6 months to assess the impact of the diet on seizure frequency.

NCT ID: NCT02261753 Terminated - Cortical Dysplasia Clinical Trials

Evaluating Dietary Intervention Before surgicaL Treatment for Epilepsy

EDIBLE
Start date: October 2014
Phase: N/A
Study type: Interventional

The investigators are undertaking the first European Randomised Controlled Trial (RCT) for epilepsy surgery in children with FCD type II, to prospectively evaluate the role of the KD prior to surgery in improving seizure outcome. The investigators will evaluate the role of KD as a disease-modifying treatment to achieve seizure control and improve neurodevelopment and quality of life. Children age 3 - 15 years with pharmacoresistant epilepsy believed to be the result of focal cortical dysplasia type II, considered to be surgically treatable, will be randomised to either receive 6m treatment presurgery with a ketogenic diet, or to proceed direct to surgery (no pretreatment). Primary outcome will be the time to achieve a period of 6 months of seizure freedom from the date of randomisation. Tissue resected at surgery will also be evaluated with regard to the degree of any methylation of DNA.

NCT ID: NCT02241798 Terminated - Epilepsy Clinical Trials

Pre-oxygenation and Measures of Gas Exchanges During Seizures in the Epilepsy Monitoring Unit

Start date: August 2013
Phase: N/A
Study type: Interventional

The primary goal of the study is to assess the effect of pre-oxygenation on oxygen and carbon dioxide levels during seizures in patients admitted at the Epilepsy Monitoring Unit (EMU). The investigators hypothesize that providing oxygen prior to seizures will help eliminate the drops in changes seen during seizures, such as the drop in oxygen saturation and increase in carbon dioxide levels. Research will be done on patients that are admitted to the EMU specifically to have seizures occur and to be recorded on video electroencephalography (vEEG), and the only research intervention will be the use of oxygen prior to some of the seizures. The importance of this research relates to the phenomenon of sudden unexplained death in epilepsy patients (SUDEP). SUDEP cases are typically patients with epilepsy who are found dead by their families in the morning, without a clear cause for death. The risk of SUDEP is as high as 9.3 per 1000 person-years (Shorvon and Tomson 2011). There may be multiple mechanisms for SUDEP to occur, however a leading hypothesis is a decrease in ventilation during the seizure leading to hypoxia. Blood oxygen saturation levels have been found to decrease significantly in 25-50% of patients during or shortly after a seizure while being monitored in hospitals. In rare situations, a significantly lowered oxygen level may trigger a cascade of events from which the body may not be able to recover, leading to SUDEP. In animal models, providing oxygen prior to seizures occurring has been shown to eliminate oxygen desaturation, but more importantly eliminate mortality in animals prone to death due to seizures. Pre-oxygenation is a standard procedure during rapid-sequence induction anesthesia as it reduces the risk of oxygen desaturation during the apneic period of the procedure. On room air, the estimated duration of safe apnea is 1 minute, but this can increase to 8 minutes following pre-treatment with high FiO2 (Weingart and Levitan 2012). This is primarily due to oxygen replacing nitrogen within alveoli, creating a reservoir of oxygen within the lungs from which transfer to the bloodstream can continue despite the lack of ventilation. The apneic episode during seizures should benefit from the same principle. The main purpose of the Epilepsy Monitoring Unit (EMU) is to evaluate patients to better characterize seizures, to identify the main seizure focus. In addition to standard EEG with electrodes on the scalp, some patients require invasive localization of the epileptic focus by surgically placing electrodes within the skull (often referred to as GRID patients) on or within the brain, with the goal of being able to resect the area that is causing seizures. To identify where seizure originate electrically, it requires that seizures occur during the vEEG procedure. To provoke seizures, medications are typically lowered, and both partial seizures and those with secondary generalization to full tonic-clonic (GTC) seizures will occur. Prior research has shows that oxygen desaturation below 90% occurs with some complex partial seizures, but hypoxia is more common and more profound with GTCs. Some centers use oxygen saturation and CO2 monitors as their standard of care, and at NYULMC the investigators also have the capability for both for clinical usage. Oxygen is not currently a mandated standard-of-care, but is often provided by nasal prongs following seizures as part of the post-ictal nursing care, though there is no outcome data to support its use. It is unknown whether pre-treatment with oxygen will reduce the rate of oxygen desaturations clinically, as seen in animal models, and this is the goal of this research project.

NCT ID: NCT02172755 Terminated - Epilepsy Clinical Trials

Single-dose and Steady-state Pharmacokinetics of BIA 2-093 and Its Metabolites

Start date: June 2002
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the effects of age on the pharmacokinetic profile of BIA 2-093 and its active metabolites.

NCT ID: NCT02161185 Terminated - Epilepsy Clinical Trials

A Long-term Safety and Tolerability Study of USL261 in Patients With Seizure Clusters

Start date: May 2014
Phase: Phase 3
Study type: Interventional

The purpose of this study is to examine the long-term safety and tolerability of USL261 in the treatment of seizure clusters.

NCT ID: NCT02134366 Terminated - Epilepsy Clinical Trials

Clobazam Use in Epilepsia Partialis Continua - Pilot Study

Start date: July 2014
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate whether clobazam, brand name Onf®, is more effective as an adjunctive or monotherapy in terminating Epilepsia Partialis Continua (EPC) than either lorazepam and/or clonazepam.